the awareness of RSV amongst pregnant women and healthcare professionals (HCPs), and
 attitudes towards clinical trials and routine implementation of antenatal RSV vaccination.
Separate questionnaires for pregnant women and HCPs were distributed within four hospitals in South England (July 2017-January 2018).
Responses from 314 pregnant women and 204 HCPs (18% obstetricians, 75% 82 midwives, 7% unknown) were analyzed. Most pregnant women (88%) and midwives (66%) had no/very little awareness of RSV, unlike obstetricians (14%). Amongst pregnant women, 29% and 75% would likely accept RSV vaccination as part of a trial, or if routinely-recommended, respectively. Younger women (16-24 years), those of 21-30 weeks’ gestation, and with experience of RSV were significantly more likely to participate in trials (OR: 1.42 [1.72-9.86]; OR: 2.29 [1.22-4.31]; OR: 9.07 [1.62-50.86], respectively). White-British women and those of 21-30 weeks’ gestation were more likely to accept routinely recommended vaccination (OR: 2.16 [1.07-4.13]; OR: 2.10 [1.07-4.13]). Obstetricians were more likely than midwives to support clinical trials (92% vs. 68%, OR: 2.50, 1.01-6.16) and routine RSV vaccination (89% vs. 79%, OR: 4.08, 1.53-9.81), as were those with prior knowledge of RSV, and who deemed it serious.
RSV awareness is low amongst pregnant women and midwives. Education will be required to support successful implementation of routine antenatal 4 vaccination. Research is needed to understand reasons for vaccine hesitancy amongst pregnant women and HCPs, particularly midwives.
- RESPIRATORY SYNCYTIAL VIRUS
- clinical trials